Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | MC4R | P32245 | 3/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HCN1 | O60741 | 1/20 | 0.36 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405241 | 0.91 | TP53 (0.46) | LMNATHRBBDKRB1TP53HCN1 | |
| SCHEMBL3412504 | 0.90 | BDKRB1 (0.43) | BDKRB1 | |
| SCHEMBL3406194 | 0.89 | BDKRB1 (0.43) | LMNATHRBBDKRB1TP53 | |
| SCHEMBL3408262 | 0.89 | BDKRB1 (0.42) | BDKRB1 | |
| SCHEMBL3403262 | 0.86 | TP53 (0.39) | LMNATHRBBDKRB1TP53HCN1 | |
| SCHEMBL3408994 | 0.85 | TP53 (0.45) | LMNATHRBBDKRB1TP53HCN1 | |
| SCHEMBL3402965 | 0.85 | TP53 (0.41) | MAPTLMNABDKRB1TP53HCN1 | |
| SCHEMBL4375298 | 0.85 | BDKRB1 (0.45) | BDKRB1 | |
| SCHEMBL3409952 | 0.84 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL2570760 | 0.82 | BDKRB1 (0.52) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541573-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-09-24 | — | — | US | claimed |
| EP-2254867-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal Gmbh (DE) | 2010-12-01 | — | — | EP | claimed |
| US-20090298812-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-12-03 | — | — | US | claimed |
| WO-2009109364-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-11 | — | — | WO | claimed |
| US-8541573-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20090298812-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298812-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | MAPT 3765/4885LMNA 2316/4885THRB 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.